{"abstract":"The Food and Drug Administration (FDA or Agency) is reopening the comment period for the notice entitled \"International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; 4F-MDMB-BICA (4F-MDMB-BUTICA); Brorphine; Metonitazene; Eutylone (bk-EBDB); BMDP (3,4-Methylenedioxy-N-benzylcathinone); Kratom (mitragynine, 7-hydroxymitragynine); Phenibut\" that appeared in the Federal Register of July 23, 2021. The Agency is taking this action to allow interested persons additional time to submit comments. These comments will be considered in preparing a response from the United States to the World Health Organization (WHO) regarding the abuse liability and diversion of these drugs. WHO will use this information to consider whether to recommend that certain international restrictions be placed on these drug substances.","action":"Notice; reopening comment period.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/08/16/2021-17498.html","cfr_references":[],"citation":"86 FR 45738","comment_url":null,"comments_close_on":"2021-08-24","correction_of":null,"corrections":[],"dates":"FDA is reopening the comment period for the notice published July 23, 2021 (86 FR 39038). Submit either electronic or written comments by August 24, 2021.","disposition_notes":null,"docket_ids":["Docket No. FDA-2021-N-0739"],"dockets":[{"supporting_documents":[],"agency_name":"FDA","documents":[{"comment_count":8,"comment_start_date":"2021-08-16","updated_at":"2023-02-28T20:21:38.057-05:00","comment_url":"https://www.regulations.gov/commenton/FDA-2021-N-0739-1300","allow_late_comments":null,"id":"FDA-2021-N-0739-1300","comment_end_date":null,"regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"FDA-2021-N-0739","title":"International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; 4F-MDMB-BICA (4F-MDMB-BUTICA); Brorphine; Metonitazene; Eutylone (bk-EBDB); BMDP (3,4-Methylenedioxy-N-benzylcathinone); Kratom (mitragynine, 7-hydroxymitragynine); Phenibut; Request for Comments"}],"document_number":"2021-17498","effective_on":null,"end_page":45739,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/08/16/2021-17498.xml","html_url":"https://www.federalregister.gov/documents/2021/08/16/2021-17498/international-drug-scheduling-convention-on-psychotropic-substances-single-convention-on-narcotic","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-17498?publication_date=2021-08-16","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-08-16/2021-17498/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":2825,"last_updated":"2026-10-23 08:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-08-16/pdf/2021-17498.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-17498.pdf?1628712923","publication_date":"2021-08-16","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/08/16/2021-17498.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":8,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2021-N-0739","supporting_documents_count":0,"docket_id":"FDA-2021-N-0739","document_id":"FDA-2021-N-0739-1300","regulation_id_number":null,"title":"International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; 4F-MDMB-BICA (4F-MDMB-BUTICA); Brorphine; Metonitazene; Eutylone (bk-EBDB); BMDP (3,4-Methylenedioxy-N-benzylcathinone); Kratom (mitragynine, 7-hydroxymitragynine); Phenibut; Request for Comments","checked_regulationsdotgov_at":"2023-03-01T01:21:37Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":45738,"subtype":null,"title":"International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; 4F-MDMB-BICA (4F-MDMB-BUTICA); Brorphine; Metonitazene; Eutylone (bk-EBDB); BMDP (3,4-Methylenedioxy-N-benzylcathinone); Kratom (mitragynine, 7-hydroxymitragynine); Phenibut; Reopening Comment Period","toc_doc":"Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; 4F-MDMB-BICA (4F-MDMB-BUTICA); Brorphine; Metonitazene; Eutylone (bk-EBDB); BMDP (3,4-Methylenedioxy-N-benzylcathinone); Kratom (mitragynine, 7-hydroxymitragynine); Phenibut; Reopening Comment Period","toc_subject":"International Drug Scheduling:\n","topics":[],"type":"Notice","volume":86}